Case Report: Posterior reversible encephalopathy syndrome after lenvatinib treatment for hepatocellular carcinoma
BackgroundPosterior reversible encephalopathy syndrome (PRES) is characterized by headaches, vision loss, confusion, encephalopathy, seizures, and reversible focal edema on neuroimaging. Early recognition and treatment of PRES are essential to prevent severe complications. Lenvatinib is a multi-targ...
Zapisane w:
| Główni autorzy: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Frontiers Media S.A.
2025-03-01
|
| Seria: | Frontiers in Pharmacology |
| Hasła przedmiotowe: | |
| Dostęp online: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1487009/full |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|